{
  "id": "63f04546f36125a426000024",
  "type": "summary",
  "question": "What is the mechanism of action of Mitapivat?",
  "ideal_answer": "Mitapivat, an oral activator of pyruvate kinase in red blood cells, has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
    "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
    "http://www.ncbi.nlm.nih.gov/pubmed/35988546"
  ],
  "snippets": [
    {
      "text": "A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent \u03b1-thalassaemia or \u03b2-thalassaemia: an open-label, multicentre, phase 2 study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \u03b1-thalassaemia or NTD \u03b2-thalassaemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}